VetSheet

替米沙坦

Telmisartan

4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid

血管張力素II受體拮抗劑 (ARB)PO狗貓

別名: Semintra

由 VetSheet 獸醫團隊審訂更新於 2026年4月5日本內容以實證獸醫文獻為本

0.5-1 mg/kgPO· q24h
— 🐕

劑量為持牌獸醫專業人員的臨床參考。請務必對照最新藥品說明書及個別病患確認。

各物種劑量

🌎 NA — North America🌍 EU — Europe

狗

適應症劑量途徑頻次療程地區
Protein-losing nephropathy and hypertension0.5-1 mg/kgPOq24h—🌍 EU
  • Protein-losing nephropathy and hypertension: Limited information; successful case reports exist for use in combination with amlodipine.

貓

適應症劑量途徑頻次療程地區
Reduction of proteinuria associated with chronic kidney disease1 mg/kgPOq24h—🌍 EU
Treatment of systemic hypertension2 mg/kgPOq24h—🌍 EU
  • Reduction of proteinuria associated with chronic kidney disease: Authorized indication. Use 4 mg/ml solution.
  • Treatment of systemic hypertension: Authorized indication. Use 10 mg/ml solution.

劑量為持牌獸醫專業人員的臨床參考。請務必對照最新藥品說明書及個別病患確認。

正在為病患診症？VetSheet 的 AI 會把藥物、劑量與療程直接寫入結構化診症筆記。了解 VetSheet 如何運作

概覽

​替米沙坦 (Telmisartan)​ 是一種血管張力素II受體拮抗劑 (ARB)，在獸醫學中主要用於管理​貓慢性腎病 (CKD)​ 以減少蛋白尿，以及治療貓的​全身性高血壓​。本品為口服液劑，通常耐受性良好。

​臨床警告：​ 尚未評估替米沙坦用於控制高於 200 mmHg 全身性高血壓的安全性與療效。對於出現低血壓臨床症狀或正在接受全身麻醉的貓，強烈建議監測血壓。

​臨床提示：​ 在延緩患有 CKD（IRIS 分期 IIa 至 IV）貓咪6個月內的蛋白尿惡化方面，替米沙坦的療效似乎與貝那普利 (benazepril) 相當。

作用機制

Telmisartan is a specific Angiotensin II receptor (type AT1) antagonist. By blocking this receptor, it inhibits the detrimental effects of angiotensin II, including:

  • Vasoconstriction → lowers systemic blood pressure.
  • Aldosterone synthesis → reduces sodium and water retention.
  • Renal, vascular, and cardiac remodelling.

In the kidneys, blocking angiotensin II reduces glomerular capillary hypertension and decreases protein in the glomerular filtrate, which helps prevent the triggering or potentiation of interstitial fibrosis.

安全性與警告

禁忌症

  • Breeding cats
  • Pregnant cats
  • Lactating cats
  • Cats under 6 months of age

不良反應

  • Regurgitation
  • Vomiting
  • Diarrhoea
  • Increased ALT activity (rare, transient)
  • Hypotension
  • Decreased RBC count
  • Increased BUN

注意事項

​Blood Pressure Monitoring:​ Recommended in cats that develop clinical signs referable to hypotension or cats undergoing general anaesthesia. ​Severe Hypertension:​ Safety and efficacy for management of systemic hypertension above 200 mmHg has not been investigated. ​Hepatic Monitoring:​ Rare increases in ALT activity have been reported, though they typically resolve within a few days of stopping therapy.

藥物相互作用

AmlodipineMinor

Safe concurrent use for hypertension; no clinical evidence of hypotension at recommended doses.

ACE inhibitors (e.g., benazepril)Major

Avoid concurrent use due to potential for excessive hypotension and renal impairment.

監測

  • Systemic blood pressure
  • Urine protein:creatinine ratio (UPC)
  • Renal parameters (BUN, creatinine)
  • Liver enzymes (ALT)
  • Red blood cell count / PCV

過量

In healthy cats administered 5 times the recommended dose for 6 months, observed effects included decreases in blood pressure, decreases in red blood cell (RBC) count, and increases in blood urea nitrogen (BUN).

可用產品

劑型

  • 4 mg/ml oral solution
  • 10 mg/ml oral solution

獸醫用

  • Semintra 4 mg/ml oral solution
  • Semintra 10 mg/ml oral solution

各地核准狀態

United States✓ 已核准處方藥FDA/CVM
🐈 Cats
European Union✓ 已核准處方藥EMA
🐈 Cats

POM-V

United Kingdom✓ 已核准處方藥VMD
🐈 Cats

POM-V

暫無法規資料: 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU

儲存與穩定性

Normal precautions should be observed. Store at room temperature and keep the bottle tightly closed.

飼主須知

  • ​給藥方式：​ 請嚴格按照獸醫的指示給藥，通常為每天一次。大多數貓咪都能很好地接受這種口服液，可以直接滴入口中或與少量食物混合餵食。
  • ​副作用：​ 請注意輕微的腸胃不適，如嘔吐、腹瀉或反胃。這些症狀通常是暫時的。
  • ​低血壓跡象：​ 如果您的寵物顯得異常嗜睡、虛弱或步伐不穩，請立即聯繫您的獸醫，因為這可能是血壓降得太低的跡象。
  • ​持續用藥：​ 除非獸醫指示，否則請勿突然停止給藥，因為此藥物用於控制慢性疾病。

VetSheet 藥物參考供持牌獸醫專業人員作臨床決策輔助之用，不能取代專業判斷或廠方最新藥品說明書。